Med-Mastodon

0 posts0 participants0 posts today

AuscandocThe <a href="https://med-mastodon.com/tags/LDL" class="mention hashtag" rel="tag">#LDL</a> cumulative exposure hypothesis: evidence and practical applications | <a href="https://med-mastodon.com/tags/Nature" class="mention hashtag" rel="tag">#Nature</a> Reviews <a href="https://med-mastodon.com/tags/Cardiology" class="mention hashtag" rel="tag">#Cardiology</a> <a href="https://www.nature.com/articles/s41569-024-01039-5" target="_blank" rel="nofollow noopener noreferrer" translate="no">https://www.nature.com/articles/s41569-024-01039-5</a> “Maintaining low levels of LDL-cholesterol (LDL-C) over time decreases the number of LDL particles trapped within the artery wall, slows the progression of atherosclerosis and, by delaying the age at which mature atherosclerotic plaques develop, substantially reduces the lifetime risk of <a href="https://med-mastodon.com/tags/ASCVD" class="mention hashtag" rel="tag">#ASCVD</a> events.”

Viet Le, MPAS PA-C FACC FAHAGreat intro to @SVM_tweets by @herbaronowMD at the <a href="https://med-mastodon.com/tags/23FellowsAPP" class="mention hashtag" rel="tag">#23FellowsAPP</a> course.<a href="https://med-mastodon.com/tags/VascularMedicine" class="mention hashtag" rel="tag">#VascularMedicine</a> so important to <a href="https://med-mastodon.com/tags/ASCVD" class="mention hashtag" rel="tag">#ASCVD</a> management. @APAC_Cardiology <a href="https://med-mastodon.com/tags/PhysicianAssociate" class="mention hashtag" rel="tag">#PhysicianAssociate</a> <a href="https://med-mastodon.com/tags/HeartPA" class="mention hashtag" rel="tag">#HeartPA</a>

Viet Le, MPAS PA-C FACC FAHAHere, reppin’ @APAC_Cardiology at @SVM_tweets APP course in <a href="https://med-mastodon.com/tags/ATL" class="mention hashtag" rel="tag">#ATL</a>. <a href="https://med-mastodon.com/tags/PAD" class="mention hashtag" rel="tag">#PAD</a> is the oft forgotten 3rd leg of <a href="https://med-mastodon.com/tags/ASCVD" class="mention hashtag" rel="tag">#ASCVD</a>🦵🏾PAD = higher ASCVD events than those w/prior MI/CVA 🦵🏾Early dx and intensive tx = ⬇️MACE/MALE 🦵🏾👀 for it, use ABI!

Viet Le, MPAS PA-C FACC FAHA<a href="https://med-mastodon.com/tags/PAD" class="mention hashtag" rel="tag">#PAD</a> - the forgotten <a href="https://med-mastodon.com/tags/ASCVD" class="mention hashtag" rel="tag">#ASCVD</a> component.🦵🏾MI/CVA events higher in PAD than in prior MI/CVA pts!!!! 🦵🏾Low use of statins/other LLT in PAD 👀😮 🦵🏾<a href="https://med-mastodon.com/tags/LLT" class="mention hashtag" rel="tag">#LLT</a> effective in PAD: statinize!<a href="https://med-mastodon.com/tags/acc23" class="mention hashtag" rel="tag">#acc23</a>

AskPippa🇨🇦One in three <a href="https://c.im/tags/SouthAsians" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#SouthAsians</a> with <a href="https://c.im/tags/ASCVD" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#ASCVD</a> on statins are eligible for icosapent ethyl (IPE). IPE should be considered for this high-risk population. Story I wrote for the <a href="https://c.im/tags/MedicalPost" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#MedicalPost</a>. (Sorry, password protected for <a href="https://c.im/tags/doctors" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#doctors</a> and <a href="https://c.im/tags/pharmacists" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#pharmacists</a>). Highlights: A third of South Asians in Canada with known atherosclerotic <a href="https://c.im/tags/cardiovascular" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#cardiovascular</a> disease (ASCVD) and who take <a href="https://c.im/tags/statins" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#statins</a> would qualify to get additional treatment with icosapent ethyl (IPE).This is a significant-sized population who could benefit from the additional lowering of triglycerides using IPE, according to a study presented at the recent annual meeting of the Canadian Cardiovascular Society (<a href="https://c.im/tags/CCS" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#CCS</a>). This year’s CCS had 1,400 in-person delegates, over 350 online delegates and 130 sessions.However, a major study, the REDUCE-IT trial driving the use of IPE had very few non-white participants, according to a poster abstract presented by Canadian researchers.IPE is a highly purified preparation of <a href="https://c.im/tags/eicosapentaenoic" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#eicosapentaenoic</a> acid (EPA), which is an omega-3 fatty acid. It is used to treat severe hypertriglyceridemia (500 mg/dL and over). It is used as an adjunct to statin therapy to reduce the risk of cardiovascular events in people whose serum <a href="https://c.im/tags/triglyceride" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#triglyceride</a> levels are over 150 mg/dL. <a href="https://c.im/tags/MedMastodon" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#MedMastodon</a><a href="https://www.canadianhealthcarenetwork.ca/one-three-south-asians-ascvd-statins-are-eligible-icosapent-ethyl" rel="nofollow noopener noreferrer" target="_blank">https://www.canadianhealthcarenetwork.ca/one-three-south-asians-ascvd-statins-are-eligible-icosapent-ethyl</a>

Recent searches

Search options

Administered by:

Server stats:

#ascvd